CG Oncology, Financials
| CGON Stock | 33.90 0.05 0.15% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.28 | 0.14 |
|
| |||||
| Current Ratio | 8.78 | 13.6189 |
|
|
Investors should never underestimate CG Oncology,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CG Oncology,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in CG Oncology, Common.
Net Income |
|
CGON |
Understanding current and past CG Oncology, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CG Oncology,'s financial statements are interrelated, with each one affecting the others. For example, an increase in CG Oncology,'s assets may result in an increase in income on the income statement.
CG Oncology, Stock Summary
CG Oncology, competes with Eliem Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. CG Oncology, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US1569441009 |
| CUSIP | 156944100 |
| Location | California; U.S.A |
| Business Address | 400 Spectrum Center |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | cgoncology.com |
| Phone | 949 409 3700 |
CG Oncology, Key Financial Ratios
| Operating Margin | (42.47) % | ||||
| Price To Sales | 4,451 X | ||||
| Revenue | 204 K | ||||
| EBITDA | (55.43 M) | ||||
| Net Income | (48.61 M) |
CGON Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CG Oncology,'s current stock value. Our valuation model uses many indicators to compare CG Oncology, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CG Oncology, competition to find correlations between indicators driving CG Oncology,'s intrinsic value. More Info.CG Oncology, Common is rated fourth in operating margin category among its peers. It is the top company in current valuation category among its peers . At this time, CG Oncology,'s Operating Profit Margin is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CG Oncology,'s earnings, one of the primary drivers of an investment's value.CG Oncology, Common Systematic Risk
CG Oncology,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CG Oncology, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on CG Oncology, Common correlated with the market. If Beta is less than 0 CG Oncology, generally moves in the opposite direction as compared to the market. If CG Oncology, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CG Oncology, Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CG Oncology, is generally in the same direction as the market. If Beta > 1 CG Oncology, moves generally in the same direction as, but more than the movement of the benchmark.
CG Oncology, November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CG Oncology, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CG Oncology, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of CG Oncology, Common based on widely used predictive technical indicators. In general, we focus on analyzing CGON Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CG Oncology,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 13.65 | |||
| Value At Risk | (4.77) | |||
| Potential Upside | 4.67 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.036 | Quarterly Revenue Growth 1.727 |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.